**Guideline Page and Request**

**Panel Discussion**

Based on panel discussion and data in the noted references, the panel consensus was to add the following regimens for the new Adult Medulloblastoma and Supratentorial PNET section:

**Adult Medulloblastoma and Supratentorial PNET**

- **Adjuvant Treatment**
  - Weekly vincristine during craniospinal radiation therapy followed by either of the following regimens:
    - Cisplatin, cyclophosphamide, and vincristine
    - Cisplatin, lomustine, and vincristine

- **Recurrence/Salvage therapy**
  - No prior chemotherapy
    - High-dose cyclophosphamide ± etoposide
    - Carboplatin, etoposide, and cyclophosphamide
    - Cisplatin, etoposide, and cyclophosphamide
    - High-dose chemotherapy with autologous stem cell reinfusion in patients who achieve a complete response with conventional doses of salvage chemotherapy or have no residual disease after re-resection
  - Prior chemotherapy
    - High-dose cyclophosphamide ± etoposide
    - Oral etoposide
    - Temozolomide ± 13-cis retinoic acid
    - High-dose chemotherapy with autologous stem cell reinfusion in patients who achieve a complete response with conventional doses of salvage chemotherapy or have no residual disease after re-resection

**References**

See the “Principles of Brain and Spinal Cord Tumor Systemic Therapy” pages in the NCCN Guidelines™ for Central Nervous System Cancers. (www.nccn.org)

<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>References</th>
<th>Vote</th>
</tr>
</thead>
</table>
| **BRAIN-D** Internal request: Add a section for Adult Medulloblastoma and Supratentorial PNET in the Principles of Systemic Therapy pages to correspond with the new algorithm in the Central Nervous System Cancers Guideline. | Based on panel discussion and data in the noted references, the panel consensus was to add the following regimens for the new Adult Medulloblastoma and Supratentorial PNET section: **Adult Medulloblastoma and Supratentorial PNET**
- Adjuvant Treatment
  - Weekly vincristine during craniospinal radiation therapy followed by either of the following regimens:
    - Cisplatin, cyclophosphamide, and vincristine
    - Cisplatin, lomustine, and vincristine

- Recurrence/Salvage therapy
  - No prior chemotherapy
    - High-dose cyclophosphamide ± etoposide
    - Carboplatin, etoposide, and cyclophosphamide
    - Cisplatin, etoposide, and cyclophosphamide
    - High-dose chemotherapy with autologous stem cell reinfusion in patients who achieve a complete response with conventional doses of salvage chemotherapy or have no residual disease after re-resection
  - Prior chemotherapy
    - High-dose cyclophosphamide ± etoposide
    - Oral etoposide
    - Temozolomide ± 13-cis retinoic acid
    - High-dose chemotherapy with autologous stem cell reinfusion in patients who achieve a complete response with conventional doses of salvage chemotherapy or have no residual disease after re-resection | See the “Principles of Brain and Spinal Cord Tumor Systemic Therapy” pages in the NCCN Guidelines™ for Central Nervous System Cancers. (www.nccn.org) | **YES** 14 | **NO** 0 | **ABSTAIN** 0 |